Associate Director for Regulatory Affairs, OHOP and OCE (Acting), CDER, FDA
Tamy Kim is the Associate Director for Regulatory Affairs (ADRA) in the Office of Oncology and Hematology Products (OHOP) and Acting ADRA in the Oncology Center of Excellence (OCE) at the FDA. In OHOP, her responsibilities include developing policies related to review processes, including...
Read More →
Associate Director for Patient Outcomes (Acting), OCE, FDA
Paul G. Kluetz, M.D., is a medical oncologist and the Acting Associate Director of Patient Outcomes in the Oncology Center of Excellence at the U.S. FDA. He is interested in defining clinical benefit in oncology trials, the use of expedited programs such as accelerated approval and...
Read More →AK
Acting Deputy Director, Office of Device Evaluation, CDRH, FDA
Director, Center for Biologics Evaluation and Research, FDA, United States
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching...
Read More →
Deputy Director, Regulatory Programs, OCD, CDER, FDA
As Deputy Director for Regulatory Programs, Dr. Throckmorton shares the responsibility for overseeing the regulation of research, development, manufacture and marketing of prescription, over-the-counter, and generic drugs in the United States.
Associate Director for Policy, Office of Combination Products, OCPP, OC, FDA, United States
John Barlow Weiner is the Associate Director for Policy in the Food and Drug Administration's Office of Combination Products, which is tasked with ensuring the sound and consistent regulation of combination products and also with the classification and assignment for regulation of...
Read More →
